Beta-Lapachone Suppresses Non-small Cell Lung Cancer Proliferation through the Regulation of Specificity Protein 1

Biological & Pharmaceutical Bulletin
Young-Joo JeonJung-Il Chae

Abstract

Lung cancer is the leading cause of cancer-related death worldwide, and non-small cell lung cancer (NSCLC) is the most common pathological type with a reported frequency of about 85% of all cases. Despite recent advances in therapeutic agents and targeted therapies, the prognosis for NSCLC remains poor, and therefore it is important to identify the biological targets of this complex disease since a blockade of such targets would affect multiple downstream signaling cascades. β-Lapachone (β-Lap) is an antiproliferative agent that selectively induces apoptosis-related cell death in a variety of human cancer cells. However, the mechanisms of its action require further investigation. In this study, we show that treatment with β-lap triggers apoptosis and cell-cycle arrest in two NSCLC cell lines: H1299 and NCI-H358. The transcription factor specificity protein 1 (Sp1) was markedly inhibited by β-lap in a dose- and time-dependent manner. Furthermore, β-lap modulated the protein expression levels of the Sp1 regulatory genes, including cell-cycle regulatory proteins and antiapoptotic proteins, resulting in apoptosis. Taken together, our results indicate that β-lap may be a potential antiproliferative agent candidate by inducing apopto...Continue Reading

References

May 1, 1990·Journal of Ethnopharmacology·E R de AlmeidaC A Lopes
Aug 1, 1984·Journal of Medicinal Chemistry·K Schaffner-SabbaJ W Wasley
Aug 1, 1994·Planta medica·P GuiraudM Simeon de Buochberg
Mar 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·C J LiA B Pardee
Jun 20, 2001·Experimental Cell Research·S M PlanchonD A Boothman
Mar 15, 2003·Nature Reviews. Cancer·John Mann
May 2, 2003·American Journal of Respiratory and Critical Care Medicine·Huei-Ping TzengShing-Hwa Liu
Apr 3, 2004·Trends in Molecular Medicine·Mark E Ewen, Justin Lamb
Mar 22, 2005·Gene·Shijian Chu, Thomas J Ferro
Oct 8, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Stephen Safe, Maen Abdelrahim
May 23, 2006·Oncogene·E DeniaudY Leverrier
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Jul 25, 2008·American Journal of Physiology. Cell Physiology·Hsiu-Ni KungKuo-Shyan Lu
Nov 11, 2009·Nucleic Acids Research·Lishan WangTieliu Shi
Feb 1, 2011·The Lancet Oncology·William Pao, Nicolas Girard
Apr 1, 2011·European Journal of Medicinal Chemistry·Sabrina Baptista FerreiraSolange L de Castro
Apr 19, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·M Früh
Jul 24, 2013·International Journal of Oncology·Dong-Wook KimJung-Hyun Shim
Jul 16, 2014·Molecular Medicine Reports·Qing XuHongxia Zhu

❮ Previous
Next ❯

Citations

Aug 20, 2016·European Journal of Drug Metabolism and Pharmacokinetics·Marival BermejoMarta Gonzalez-Alvarez
Dec 8, 2016·Integrative Cancer Therapies·Ji-Ye KeeSeung-Heon Hong
Mar 17, 2018·Cancer Prevention Research·Stephen SafeErik Hedrick

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis